Champions Oncology (NASDAQ:CSBR) Stock Price Breaks Below Two Hundred Day Moving Average – Here’s What Happened

Champions Oncology, Inc. (NASDAQ:CSBR) shares crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $5.66 and traded as low as $4.82. Champions Oncology shares last traded at $4.95, with a volume of 11,405 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Champions Oncology from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, September 16th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, Champions Oncology presently has an average rating of “Sell”.

Champions Oncology Price Performance

The firm has a market capitalization of $66.96 million, a P/E ratio of -60.12 and a beta of 0.44. The stock has a fifty day simple moving average of $5.03 and a two-hundred day simple moving average of $5.65.

Champions Oncology (NASDAQ:CSBR) last issued its quarterly earnings data on Thursday, September 10th. The biotechnology company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.06. Champions Oncology had a negative return on equity of 25.77% and a negative net margin of 1.82%. The firm had revenue of $15.23 million during the quarter, compared to the consensus estimate of $15.04 million.

Hedge Funds Weigh In On Champions Oncology

An institutional investor recently bought a new position in Champions Oncology stock. Bank of New York Mellon Corp bought a new stake in shares of Champions Oncology, Inc. (NASDAQ:CSBR) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 21,614 shares of the biotechnology company’s stock, valued at approximately $133,000. Bank of New York Mellon Corp owned about 0.16% of Champions Oncology at the end of the most recent reporting period. Institutional investors and hedge funds own 41.30% of the company’s stock.

About Champions Oncology

Champions Oncology, Inc is a biotechnology and technology company focused on precision oncology and the development of personalized approaches to cancer treatment. The company works with pharmaceutical and biotechnology companies, academic researchers, and healthcare providers to support the discovery, development, and evaluation of cancer therapies.

Its offerings include patient-derived tumor models, including tumor avatar models, that are designed to help researchers study how individual cancers may respond to potential treatments.